Regeneron Just Moved From Underperform To Buy - Here's Why
Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) after a surprising shift in analyst sentiment?
Fiscal Year: January - December
Regeneron Pharmaceuticals, Inc. (REGN), listed on the NASDAQ, has a market capitalization of $. As of Jan 08, 2026, the stock is trading at $812.00 per share, offering investors a clear view of its current market value. Regeneron Pharmaceuticals, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 19.52, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Regeneron Pharmaceuticals, Inc. also offers a dividend yield of 0.43%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Regeneron Pharmaceuticals, Inc. (REGN) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Regeneron Pharmaceuticals, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Regeneron Pharmaceuticals, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Regeneron Pharmaceuticals, Inc. is 19.69, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Regeneron Pharmaceuticals, Inc. (REGN) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Regeneron Pharmaceuticals, Inc. (REGN) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Regeneron Pharmaceuticals, Inc. (REGN) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Regeneron Pharmaceuticals, Inc.. To access the full SS Score, consider upgrading your subscription.
Regeneron Pharmaceuticals, Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 19.52. Investors should compare these metrics with industry peers to gauge whether Regeneron Pharmaceuticals, Inc. is outperforming or underperforming within its sector.
Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) after a surprising shift in analyst sentiment?
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduce...
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January ...
Regeneron Pharmaceuticals is poised for a turnaround as Eylea's patent cliff fades and new growth drivers emerge. Dupixent and Libtayo are expected to drive robust revenue and margin expansion, with D...
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow tr...
Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin. Moreover, as of September 30, Regeneron had about $2.2 billion remaining under its authorized share repu...
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...
Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the first p...
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
TARRYTOWN, N.Y. and SOMERVILLE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., today announced a global collaboration to develop...
Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years a...
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
November's Wall Street obsession hasn't been AI. It's been healthcare.
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following retin...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of...
Regeneron Pharmaceuticals, Inc. ( REGN) Jefferies London Healthcare Conference 2025 November 17, 2025 10:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Stra...
Regeneron Pharmaceuticals, Inc. ( REGN) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 9:20 AM EST Company Participants Mark Hudson - Investor Relations Executive Isreal Lowy - Sen...
Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setti...
Regeneron Pharmaceuticals, Inc. ( REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline November 10, 2025 8:30 AM EST Company Participants Ryan Crowe - Senior Vice Pr...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 4.05B | 10.57% | Est @10.6% |
| 2026 | 4.44B | 9.56% | Analyst x5 |
| 2027 | 4.99B | 12.43% | Analyst x5 |
| 2028 | 5.75B | 15.26% | Analyst x5 |
| 2029 | 6.36B | 10.50% | Analyst x5 |
| 2030 | 7.01B | 10.28% | Analyst x5 |
| 2031 | 7.39B | 5.46% | Est @5.5% |
| 2032 | 7.73B | 4.55% | Est @4.6% |
| 2033 | 8.03B | 3.92% | Est @3.9% |
| 2034 | 8.29B | 3.25% | Est @3.2% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 3.88B | 1.00 | 3.88B |
| 2024A | 3.66B | 1.00 | 3.66B |
| 2025E | 4.05B | 1.07 | 3.78B |
| 2026E | 4.44B | 1.15 | 3.85B |
| 2027E | 4.99B | 1.24 | 4.04B |
| 2028E | 5.75B | 1.33 | 4.33B |
| 2029E | 6.36B | 1.42 | 4.46B |
| 2030E | 7.01B | 1.53 | 4.59B |
| 2031E | 7.39B | 1.64 | 4.51B |
| 2032E | 7.73B | 1.76 | 4.39B |
| 2033E | 8.03B | 1.89 | 4.25B |
| 2034E | 8.29B | 2.03 | 4.09B |
| Terminal | 175.94B | 2.03 | 86.71B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.